Dolo Teralgex

There is no image.

Method of action: Nonsteroidal Anti-Inflammatory

Treatment option:

Medically reviewed

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dolo Teralgex

Property	Description
Active ingredients	Acetaminophen and Diclofenac
Pharmacological class	Combined Analgesic, NSAID, Antipyretic
Origin	Synthetic
Form	Typically Oral Tablet or Capsule
Common Use	Symptomatic relief of pain, inflammation, and fever

What Type of Medicine is Dolo Teralgex?

Dolo Teralgex is a synthetic fixed-dose combination (FDC) product classified as a combined analgesic, antipyretic, and anti-inflammatory agent. This preparation is built to provide multimodal analgesia by including two distinct classes of active ingredients. Diclofenac, one of the primary components, belongs to the class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), specifically a phenylacetic acid derivative. The FDC design allows for a single oral route of administration via a tablet or capsule, and this combination is clinically recognized for its application in managing pain compared to either component used alone.

Composition: Acetaminophen and Diclofenac

The formulation contains the active ingredients Acetaminophen (Paracetamol) and Diclofenac (usually as Diclofenac sodium). The design involves combining an aniline derivative analgesic with the NSAID component. Both components are synthetic in origin and are utilized together to target different biological pathways related to pain and inflammation. Fixed-dose combinations containing both drugs are used in managing acute painful conditions. This suggests the combined formula helps ease discomfort by providing relief from both pain and inflammation simultaneously.

General Purpose: Multimodal Symptomatic Relief

The general purpose of Dolo Teralgex is to deliver comprehensive symptomatic relief by engaging in both central and peripheral pain inhibition. The formulation is specifically designed to capitalize on the synergistic relationship between its two components, a principle associated with combination analgesics. The Acetaminophen component primarily affects the central nervous system to help reduce pain sensation and fever, while the Diclofenac component acts at the site of injury to reduce inflammatory swelling and chemical irritation. This cooperative action aims to offer a broad response to acute pain and its accompanying symptoms.

What side effects are possible with Dolo Teralgex?

Possible Side Effects and Safety Information

The safety profile of Dolo Teralgex, as documented by official government regulatory authorities, details potential adverse reactions and restrictions for use. The information is organized to reflect the severity and likelihood of side effects across the patient population.

Adverse Reaction Classification

Side effects are officially classified by System Organ Class (SOC), which organizes potential reactions by the affected body system (e.g., Nervous System disorders, Gastrointestinal disorders). Furthermore, these reactions are designated by a formal Frequency Classification (e.g., Common, Uncommon, Rare) to indicate the statistical probability of occurrence.

Serious and Clinically Significant Risks

Official regulatory labeling identifies specific Serious Adverse Reactions that represent the most critical safety concerns associated with the medicine. These include the risk of acute liver failure (hepatotoxicity) and the risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which may be fatal. Additionally, an increased risk of serious gastrointestinal events, including bleeding, ulceration, and perforation of the stomach or intestines, is documented, which can occur at any time during use.

Safety-Related Restrictions

Contraindications (Safety-Related Restrictions/Limitations) formally prohibit the use of Dolo Teralgex in specific high-risk clinical situations or for patients with certain pre-existing conditions. For instance, its use is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. The product contains components that, if combined with other similar products, could lead to accidental overdose, and regulatory documents stress not exceeding the maximum recommended daily dose of acetaminophen.

This structured regulatory documentation provides the authoritative basis for understanding the medicine’s risk profile, defining both the common and the most serious potential events.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of this combination product is defined by the toxic effects of both Acetaminophen and Diclofenac, necessitating immediate professional attention as defined by regulatory authorities.

Documented Manifestations and Severe Outcomes An overdose may initially present with nonspecific symptoms such as nausea, vomiting, sweating (diaphoresis), pallor, and general malaise, which are associated with the Acetaminophen component. The Diclofenac component may contribute to manifestations such as headache, confusion, drowsiness, tinnitus, and abdominal discomfort. However, the most severe, life-threatening outcomes are delayed, including acute hepatic necrosis leading to liver failure, acute renal failure, and significant gastrointestinal hemorrhage. Neurological complications, such as convulsions, are also documented possibilities.

Mandatory Emergency Actions and Supportive Care Regulatory labeling strictly mandates that individuals must seek immediate medical attention for any suspected overdose, regardless of current symptoms or feeling of wellness. This requirement is due to the potential for fatal hepatic damage from Acetaminophen, which may have a delayed onset of up to 48 hours. A specific antidote, N-acetylcysteine, is available only for the Acetaminophen component; there is no specific antidote known for Diclofenac overdose. Management is primarily symptomatic and supportive, requiring hospital monitoring of hepatic function (liver enzymes) for at least 24 hours. Increased risk of severe toxicity is noted for individuals with pre-existing hepatic impairment or chronic alcohol use.

Therapeutic Uses of Dolo Teralgex

What Dolo Teralgex Treats: Main Uses and Benefits

Dolo Teralgex is considered relevant for symptomatic relief in conditions presenting with systemic or localized discomfort and inflammatory or irritative processes. The anti-inflammatory component is generally used to help relieve symptoms related to swelling, stiffness, and discomfort across various musculoskeletal conditions. This combination is generally applied across domains where additional symptomatic support is needed to address symptom clusters that may become intense or disruptive.

Key Therapeutic Applications

Dolo Teralgex is commonly used across conditions presenting with acute episodes of pain and inflammation. This is applicable in situations involving acute musculoskeletal injuries (sprains and strains), episodic pain such as menstrual pain (dysmenorrhea), and symptomatic assistance in managing expected discomfort following surgical procedures. Furthermore, it is relevant for easing the challenging symptoms of arthritis flare-ups and certain acute headache manifestations.

Quick Fact: Relief for Combined Symptoms The formulation is applied when symptoms cluster into patterns requiring supportive management, such as addressing pain and concurrent systemic fever, or managing discomfort alongside localized inflammatory swelling. The combination is used to moderate distressing symptoms and offers symptomatic relief that contributes to easing the overall symptom load during difficult episodes.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Dolo Teralgex is a fixed-dose combination product whose eligibility is strictly defined by regulatory authorities based on the combined risks of its Acetaminophen and Diclofenac components.

Contraindicated Populations (Absolute Prohibition)

Use is strictly contraindicated in patients with known hypersensitivity to Acetaminophen, Diclofenac, aspirin, or other NSAIDs, including individuals with a history of aspirin-sensitive asthma. The medicine is prohibited for patients with active gastrointestinal ulceration, bleeding, or perforation. Due to cardiovascular risks, it is contraindicated in patients with established congestive heart failure (NYHA II–IV), ischaemic heart disease, or after CABG surgery. Use is also prohibited in cases of severe hepatic failure and severe renal insufficiency.

Age and Conditional Use Restrictions

The medicine is contraindicated in the last trimester of pregnancy and generally contraindicated during lactation.
Use is not recommended or contraindicated in children under 15 years old by certain national drug authorities.
Older adults and those with significant cardiovascular risk factors (such as hypertension or smoking) or a history of GI disease require careful consideration and close medical surveillance before use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Dolo Teralgex primarily focuses on avoiding combinations that lead to additive organ toxicity or altered drug exposure.

Contraindicated and Restricted Combinations The medicine must not be co-administered with any other acetaminophen-containing products due to the formal risk of severe liver damage (hepatotoxicity). Co-use with other oral NSAIDs, including analgesic doses of Aspirin, is restricted as it significantly increases the risk of serious gastrointestinal (GI) bleeding and ulceration. Furthermore, the use of the Diclofenac component is formally contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Pharmacodynamic and Metabolic Interactions Co-administration with anticoagulants (such as Warfarin) and antiplatelet agents is documented to increase the overall risk of bleeding due to interference with hemostasis. The Diclofenac component may cause a diminished antihypertensive or natriuretic effect when taken with ACE Inhibitors, ARBs, or Diuretics. Pharmacokinetic interactions are noted, where certain strong CYP2C9 inhibitors may elevate the systemic exposure of Diclofenac. The label also specifies that chronic alcohol ingestion (three or more drinks daily) substantially amplifies the hepatotoxicity risk associated with the Acetaminophen component.

Exposure-Modifying Substances and Populations This medicine may raise the plasma concentrations of co-administered drugs like Digoxin, Lithium, and Methotrexate. Interaction considerations are formally noted for specific populations, including the Elderly or those with Volume Depletion, where co-use with certain blood pressure medicines necessitates vigilance regarding potential deterioration of renal function.

Mechanism of Action

How Dolo Teralgex Works: Mechanism of Action

The mechanism of Dolo Teralgex involves a dual action across distinct physiological systems.

Modulating Peripheral Signaling Pathways

One component of the drug acts as an enzyme inhibitor that blocks cyclooxygenase ( COX) enzymes outside of the central nervous system. By suppressing the COX enzymes, the drug limits the production of prostaglandins, which are chemical mediators that sensitize nerve endings and promote localized physiological responses. The resulting physiological effect is a reduction in peripheral nerve sensitization.

Targeting Central Discomfort and Temperature Regulation

The second component acts within the Central Nervous System (CNS), particularly in the brain and spinal cord, to modulate the processing of signals. This central action influences descending pathways to elevate the threshold for perceiving discomfort. Additionally, it directly impacts the hypothalamic thermoregulatory center, adjusting the body's 'thermostat'. This results in the key physiological changes of an altered perception of discomfort and the adjustment of the thermoregulatory set-point.

Dosage and Administration Information

How to Use Dolo Teralgex

Dolo Teralgex is an oral, fixed-dose combination medication whose usage protocol is outlined in technical documentation. The administration guidelines focus on route, quantity, timing, and duration to establish a standardized use pattern, particularly concerning the 500 mg Paracetamol and 50 mg Diclofenac Sodium unit dose.

Official Administration Guidelines

Feature	Official Instruction Summary
Route of administration	Oral via caplet or tablet.
Standard Dosing Regimen	One caplet per dose. The maximal daily dose is limited by the prescription frequency, which is typically two or three times daily.
Timing in relation to meals	The medication is instructed to be taken with food or a drink during a meal to optimize its use context.
Preparation & Handling	The unit dose must be swallowed whole and should not be crushed or chewed, a requirement tied to maintaining the intended use profile.

Duration and Population Constraints

The usage protocol emphasizes that Dolo Teralgex should be administered using the lowest effective daily dose for the shortest duration possible to align with general guidelines for NSAID-containing products. For older adults, a reduced dosage is commonly recommended, and careful monitoring of biological parameters is specified. Furthermore, the pharmaceutical form and its associated dosage are not indicated for use in children. These high-level constraints define the structured approach for administering the medication, as detailed in the official prescribing information.

Recent Clinical Evidence

Dolo Teralgex: Recent Clinical Evidence

This section provides a factual overview of the clinical research conducted for the fixed-dose combination of Acetaminophen and Diclofenac, based on findings reported in scientific and regulatory sources. This summary focuses on the structure of the evidence and the types of studies available; it is not clinical advice, nor does it provide recommendations on usage or dosing.

Evidence for Use in Acute Pain

Short-term, double-blind Randomized Controlled Trials (RCTs) were used in research exploring how symptoms change over time in conditions associated with acute or disruptive episodes, such as those related to specific procedures or acute musculoskeletal events. Research examined patient-reported outcomes describing perceived discomfort and the usage of additional pain relief measures in adult patients. Studies report patterns observed in the populations related to measured changes in pain intensity scores during the study period.

The available evidence for the combination primarily focuses on data collected during the short-term follow-up periods (hours or a few days). Evidence quality varies across studies, and long-term effects are not fully established.

Evidence for Use in Mild-to-Moderate Arthritic Pain

Research has explored the combination’s use in conditions characterized by fluctuating or episodic manifestations, which includes flare-ups associated with chronic joint conditions. The evidence for this area often relied on analytical methods such as Model-Based Meta-Analyses (MBMA), which use existing trial data to inform projections. Research examined outcomes reflecting daily functioning and pain severity in adults with conditions involving periods of heightened symptoms, such as Osteoarthritis.

There is a lack of dedicated, prospective RCTs specifically designed to assess the long-term, continuous use of the fixed-dose combination. Existing studies provide limited insight into the durability of relief, meaning certainty remains low in this specific area.

Study Duration and Research Gaps

The typical follow-up durations were limited across the main clinical studies. Data describes observations over very short-term periods. There is limited information for long-term outcomes regarding the continued use of the combination.

Research was evaluated in primarily non-elderly adult patients. Data for certain groups remain insufficient, including older adults or children. Evidence quality varies across studies, and findings were mixed when comparing the combination to high-dose monotherapy. Research provides context but does not offer individual guarantees, as the findings describe group patterns and do not establish whether an individual will respond similarly outside of the specific study conditions.

Frequently Asked Questions (FAQ)

Common questions about Dolo Teralgex (FAQ)

Q: Is Dolo Teralgex considered a narcotic or opioid pain reliever?

Official regulatory documents classify Dolo Teralgex as a fixed-dose combination product containing Acetaminophen (a non-opioid analgesic) and Diclofenac (a Non-Steroidal Anti-Inflammatory Drug, or NSAID). It is not listed as a federally controlled substance, as it does not contain opioid ingredients.

Q: How long does it usually take for Dolo Teralgex to start working (onset of action)?

Studies on the drug's components indicate that the Diclofenac portion may begin to work in less than 30 minutes after taking it. However, because official instructions advise taking the medication with food, this may slightly delay the time it takes for the body to absorb the medicine.

Q: How long do the pain-relieving effects last after a single dose?

The official prescribing information indicates a standard dosing regimen that typically involves taking the medication two or three times over a 24-hour period. This frequency is consistent with a documented duration of action for the components, often described as requiring administration every 8 to 12 hours.

Q: Can Dolo Teralgex cause drowsiness or fatigue that affects daily activities?

The official safety information for the Diclofenac component lists drowsiness (also called somnolence) and fatigue (asthenia) as possible adverse reactions. These effects are documented in regulatory reports.

Q: Does Dolo Teralgex commonly cause constipation or other digestive issues?

While the safety profile primarily addresses serious gastrointestinal risks like bleeding, official documents also include reports of less common digestive issues. These may include specific side effects such as constipation or diarrhea.

Q: Are there known interactions between Dolo Teralgex and antidepressant medications?

Official prescribing information describes that co-administration of Dolo Teralgex alongside certain types of antidepressants, specifically SSRIs (Selective Serotonin Reuptake Inhibitors), is associated with an increased risk. This combination is documented to raise the risk of serious gastrointestinal bleeding.

Q: Why do some people report feeling dizzy or lightheaded after taking Dolo Teralgex?

The regulatory safety information for the Diclofenac component includes documentation of common adverse effects that affect the nervous system. These documented side effects include reports of dizziness and headache.

Q: Why is Dolo Teralgex a prescription-only medication?

Official regulatory bodies designate Dolo Teralgex as prescription-only due to the mandated warnings associated with its combined ingredients. These warnings involve the risk of serious side effects, including liver toxicity, gastrointestinal bleeding, and potential cardiovascular thrombotic events like heart attack or stroke.

Q: Does taking Dolo Teralgex affect ability to drive or operate machinery?

Official documents state that caution is warranted regarding activities that require full attention. This statement is based on the possibility of side effects such as dizziness, drowsiness, or blurred vision which are documented to affect alertness.

Q: Can Dolo Teralgex cause stomach upset or nausea?

Yes, official safety information for the drug's components commonly lists gastrointestinal adverse reactions. These reactions include reports of nausea, vomiting, and general stomach pain.

Q: Can Dolo Teralgex affect sleep patterns or cause insomnia?

The safety profile for the Diclofenac component includes nervous system disorders among its reported adverse reactions. These reported effects may include insomnia (difficulty sleeping) or alterations in sleep, such as dream abnormalities.

Q: What is the approximate half-life of Dolo Teralgex?

The term half-life refers to how quickly the body processes the drug. Pharmacokinetic studies show that the terminal elimination half-life for the Acetaminophen component is typically around 1.9 to 2.5 hours. The Diclofenac component's half-life is shorter, approximately 1 to 2 hours.

Q: Does Dolo Teralgex affect mental alertness or cause confusion?

The official safety profile for the Diclofenac component includes documented reports of nervous system side effects. These potential reactions include confusion, depression, or anxiety.

Q: Is Dolo Teralgex used to treat nerve pain (neuropathic pain)?

Official clinical evidence summaries indicate that this medication is not primarily indicated for nerve pain. The research evidence that exists for the use of Dolo Teralgex in treating neuropathic pain is noted as being insufficiently established.

How should Dolo Teralgex be stored and disposed of?

Official Storage and Disposal Instructions

Dolo Teralgex tablets must be stored under specific environmental controls as mandated by regulatory labeling to preserve product stability. The required storage condition is Controlled Room Temperature, typically below 25 C (77 F).

Storage Requirement	Rule
Temperature	Store below 25 C and do not freeze.
Container	Keep in the original packaging and ensure the container is tightly closed to protect from moisture and light.
Child Safety	Keep out of the sight and reach of children to prevent accidental ingestion.
Disposal	Dispose of unused or expired medicine according to local regulations or a drug take-back program. Do not dispose of in wastewater or household trash.